<DOC>
	<DOC>NCT00667862</DOC>
	<brief_summary>This Phase II single dose study is designed to characterize the safety, tolerability and efficacy of i.v. panobinostat as a single-agent treatment in patients with hormone refractory prostate cancer.</brief_summary>
	<brief_title>Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criteria: Confirmed diagnosis of adenocarcinoma of the prostate Patients with metastatic hormone refractory prostate cancer Patients that have had at least one, but not more than two prior cytotoxic treatments for prostate cancer Evidence of disease progression by at least one of the following 1. two or more lesions on bone scan 2. progressive measurable disease 3. two documented increases in PSA Willing to use contraception throughout the study and for 12 weeks after study completion Exclusion criteria: History or clinical signs of CNS disease History of other cancers not curatively treated with no evidence of disease for more than 5 years Prior radiotherapy within 3 weeks of starting study treatment Prior radiopharmaceuticals (strontium, samarium) Impaired cardiac function Heart disease Liver or renal disease with impaired function Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Prostate-Specific Antigen</keyword>
	<keyword>metastatic</keyword>
	<keyword>male</keyword>
	<keyword>HRPC</keyword>
	<keyword>DACi</keyword>
</DOC>